Your session is about to expire
← Back to Search
AG-120 for Chondrosarcoma
Study Summary
This trial is testing AG-120, to see if it is safe and effective in people with chondrosarcoma that has returned or spread, and has an IDH1 mutation.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 3 trial • 187 Patients • NCT02989857Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My heart's pumping ability is below 40% as shown by recent tests.I haven't had radiotherapy or local treatment for cancer spread in the last 2 weeks.I have previously been treated with an IDH1 inhibitor.I do not have an active infection needing strong medication or unexplained high fever recently.I haven't had serious heart problems like heart failure, heart attack, or stroke in the last 6 months.I can switch or monitor my current sensitive medication before the study starts.I have brain metastases but am not currently on steroids and have been stable for 3 months.I am taking 10mg or less of prednisolone daily.I can take pills by mouth.I am not on QT-prolonging meds or can switch before the study.You are expected to live for at least four more months.I am not pregnant or have confirmed contraception use if capable of becoming pregnant.I have a tumor that can be measured and has grown by at least 20% after treatment.I do not have active hepatitis B or C, HIV, or AIDS, or my condition is well-managed.I haven't had cancer treatment or experimental drugs in the last 3 weeks.I have been diagnosed with progressive multifocal leukoencephalopathy.I have a grade 2 or 3 pelvic chondrosarcoma confirmed by biopsy.You are allergic to any part of AG-120.I have not had major surgery in the last 4 weeks or still have significant side effects from one.I am 18 years old or older.I am able to get out of my bed or chair and move around.My kidneys work well enough (creatinine clearance >= 50ml/min).My kidney function is normal.My kidney function is suitable for the trial based on a specific calculation.I am not on strong medication that affects liver enzyme activity, or I can switch if needed.I have a condition that affects how my stomach or intestines absorb medicine taken by mouth.I have recovered from side effects of previous cancer treatments.My heart's electrical activity or family history may increase my risk for irregular heartbeats.My liver is working well.My cancer is not low grade or dedifferentiated chondrosarcoma.My blood tests show my bone marrow is working well.My chondrosarcoma (grade 2 or 3) diagnosis is confirmed by a biopsy.My cancer has a confirmed IDH1 mutation.I can understand and agree to follow the study's requirements and sign the consent form.I have another cancer that needs treatment.
- Group 1: Chondrosarcoma
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What AG-120 side effects do patients need to be aware of?
"AG-120 falls into Phase 2 of clinical trials, so there is some data affirming its safety but not yet its efficacy."
Are there any other existing AG-120 trials that we can compare this one to?
"AG-120 was first studied in 2014, as noted by NCT02073994. There have been 6 completed studies thus far, with 22 more ongoing clinical trials. A large number of these live trials are based out of Baltimore, MD."
Are we still looking for participants in this trial?
"That is correct. The listing on clinicaltrials.gov verifies that this study, which was initially posted on March 4th 2020, is still recruiting patients. They need a total of 17 subjects from 3 different locations."
How many individuals are being helped by this research?
"In order to begin this clinical trial, 17 individuals who match the given inclusion criteria must be recruited. This study is conducted at multiple locations, such as Johns Hopkins Hospital (Data Analysis Only) in Baltimore, Maryland and MD Anderson Cancer Center in Houston, Texas."
Who else is applying?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger